Prot #SC291-101: A Phase 1 Study Evaluating SC291, a Hypoimmune Allogeneic CD19-Directed CAR T Cell Therapy, in Relapsed and/or Refractory B-Cell Malignancies (ARDENT)

Project: Research project

Project Details

StatusActive
Effective start/end date4/9/244/9/27

Funding

  • PPD Development (Prot #SC291-101 // Prot #SC291-101)
  • Sana Biotechnology, Inc. (Prot #SC291-101 // Prot #SC291-101)